HomeCompareBMY vs AVY

BMY vs AVY: Dividend Comparison 2026

BMY yields 4.17% · AVY yields 2.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVY wins by $144.0K in total portfolio value· pulled ahead in Year 7
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
AVY
AVY
● Live price
2.24%
Share price
$168.15
Annual div
$3.76
5Y div CAGR
57.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$264.5K
Annual income
$138,265.18
Full AVY calculator →

Portfolio growth — BMY vs AVY

📍 AVY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYAVY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + AVY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
AVY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
AVY
Annual income on $10K today (after 15% tax)
$190.07/yr
After 10yr DRIP, annual income (after tax)
$117,525.40/yr
At 15% tax rate, AVY beats the other by $83,675.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + AVY for your $10,000?

BMY: 50%AVY: 50%
100% AVY50/50100% BMY
Portfolio after 10yr
$192.5K
Annual income
$89,044.42/yr
Blended yield
46.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
AVY
Analyst Ratings
13
Buy
5
Hold
Consensus: Buy
Price Target
$221.00
+31.4% upside vs current
Range: $200.00 — $234.00
Altman Z
3.5
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
AVY buys
0
No recent congressional trades found for BMY or AVY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYAVY
Forward yield4.17%2.24%
Annual dividend / share$2.49$3.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%57.9%
Portfolio after 10y$120.5K$264.5K
Annual income after 10y$39,823.66$138,265.18
Total dividends collected$91.0K$231.2K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusHoldBuy
Analyst price target$62.73$221.00

Year-by-year: BMY vs AVY ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrAVY PortfolioAVY Income/yrGap
1$11,271$571.12$11,053$353.08+$218.00BMY
2$12,884$824.20$12,403$575.91+$481.00BMY
3$14,993$1,206.32$14,225$953.64+$768.00BMY
4$17,839$1,797.27$16,834$1,614.01+$1.0KBMY
5$21,826$2,738.11$20,831$2,818.78+$995.00BMY
6$27,643$4,289.31$27,437$5,147.36+$206.00BMY
7← crossover$36,534$6,955.64$39,362$10,004.60$2.8KAVY
8$50,861$11,770.13$63,298$21,180.73$12.4KAVY
9$75,402$20,980.23$117,993$50,263.39$42.6KAVY
10$120,504$39,823.66$264,517$138,265.18$144.0KAVY

BMY vs AVY: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

AVYMaterials

Avery Dennison Corporation manufactures and markets pressure-sensitive materials and products in the United States, Europe, Asia, Latin America, and internationally. The company's Label and Graphic Materials segment offers pressure-sensitive label and packaging materials; and graphics and reflective products under the Fasson, JAC, Avery Dennison, and Mactac brands, as well as durable cast and reflective films. It provides its products to the home and personal care, beer and beverage, durables, pharmaceutical, wine and spirits, and food market segments; architectural, commercial sign, digital printing, and other related market segments; construction, automotive, and fleet transportation market segments, as well as traffic and safety applications; and sign shops, commercial printers, and designers. The company's Retail Branding and Information Solutions segment designs, manufactures, and sells brand embellishments, graphic tickets, tags and labels, and sustainable packaging solutions, as well as offers creative services; radio-frequency identification products; visibility and loss prevention solutions; price ticketing and marking solutions; care, content, and country of origin compliance solutions; and brand protection and security solutions. It serves retailers, brand owners, apparel manufacturers, distributors, and industrial customers. The company's Industrial and Healthcare Materials segment offers tapes; pressure-sensitive adhesive based materials and converted products; medical fasteners; and performance polymers under the Fasson, Avery Dennison, and Yongle brands. It serves automotive, electronics, building and construction, general industrial, personal care, and medical markets. The company was formerly known as Avery International Corporation and changed its name to Avery Dennison Corporation in 1990. Avery Dennison Corporation was founded in 1935 and is headquartered in Glendale, California.

Full AVY Calculator →
📬

Get this BMY vs AVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.